Evaluation of the Efficacy and Treatment-Emergent Adverse Events of Deuruxolitinib for Moderate to Severe Alopecia Areata: A Dose-Ranging Meta-Analysis of 1,372 Randomized Patients

The meta-analysis of 1,372 randomized patients across three trials indicates that deuruxolitinib is effective in treating moderate to severe alopecia areata (AA), showing significant improvements in hair regrowth as measured by the SALT score and patient satisfaction (SPRO). Patients experienced notable improvements, with many achieving 75% to 90% improvement from baseline. However, treatment-emergent adverse events (TEAEs) such as elevated creatinine kinase levels, headaches, and acne (notably at the 12 mg dose) were observed, though they were generally manageable. The study concludes that while deuruxolitinib is promising for AA treatment, further research is needed to ensure long-term safety.